Physician profile
Brian York
NPI 1538890710
$393.33
in general payments reported to CMS, 2019-2025
15 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $18.20 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $78.38 | 2025 | Symbravo, Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $52.26 | 2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.58 | 2025 | Caplyta |
| Abbvie INC. | $34.72 | 2025 | |
| Springworks Therapeutics, INC. | $22.95 | 2025 | Gomekli |
| Tris Pharma INC | $18.31 | 2025 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2025 | |
| Aurinia Pharma U.S., INC. | $18.20 | 2024 | Lupkynis |
| Vanda Pharmaceuticals INC. | $17.57 | 2025 | Fanapt |
| Corcept Therapeutics | $17.30 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $17.07 | 2025 | Rexulti |
| Lilly USA, LLC | $16.32 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $16.02 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $14.50 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $13.93 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian York listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.